Spotlight Therapeutics, Inc., a Hayward, California-based biotechnology company applying new insights to develop cell-targeted in vivo CRISPR gene editing biologics, raised $36.5M in Series B financing.
The round was co-led by new investors GordonMD Global Investments and EPIQ Capital Group, with participation from Magnetic Ventures, as well as existing investors GV (formerly Google Ventures) and Emerson Collective and other investors. Craig Gordon, M.D., Founder, CEO and CIO of GordonMD Global Investments, joined Spotlight Therapeutics’ Board of Directors.
The company intends to use the funds to continue to develop its platform.
Led by Mary Haak-Frendscho, Ph.D., President and CEO, Spotlight Therapeutics is a biotechnology company advancing a pipeline of cell-targeted in vivo CRISPR gene editing therapies. Spotlight’s proprietary technology platform TAGE (Targeted Active Gene Editors) is a new class of biologics, CRISPR effectors engineered for direct delivery in vivo, to achieve cell-selective therapeutic genome editing. The pipeline is advancing its modular programmable CRISPR effectors towards clinical studies in immuno-oncology, ophthalmic diseases and hemoglobinopathies.
The company announced the promotion of Mary Janatpour, Ph.D. to CSO and the appointments of Peter Cameron, Ph.D., Executive Director of Technology and Cynthia Li, PhD, VP, Corporate and Business Development.